Transdermal Buprenorphine: utilization trends in United Kingdom primary care practice
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Presentations + Posters
- By: ZIN, Che Suraya (The University of Nottingham, Division for Social Research in Medicines and Health, Nottingham, United Kingdom)
- Co-author(s): Chen, L. (Division for Social Research in Medicines and Health,, Nottingham, United Kingdom)
Knaggs, R. (kulliyyah of Pharmacy, International Islamic University Malaysia, Nottingham, United Kingdom)
Background information:Transdermal buprenorphine low doses (5, 10 or 20 µg/hour for 7 days) and the high doses (35, 52.5 or 70 µg/hour for 4 days) are increasingly being used for the treatment of chronic cancer and noncancer pain. Although these formulations have shown better persistence with therapy, there is limited data available on factors.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.